These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 18766173)
1. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Dobrikova EY; Broadt T; Poiley-Nelson J; Yang X; Soman G; Giardina S; Harris R; Gromeier M Mol Ther; 2008 Nov; 16(11):1865-72. PubMed ID: 18766173 [TBL] [Abstract][Full Text] [Related]
2. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Goetz C; Gromeier M Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Foreman PM; Friedman GK; Cassady KA; Markert JM Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Brown MC; Gromeier M Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317 [TBL] [Abstract][Full Text] [Related]
6. Recombinant Poliovirus for Cancer Immunotherapy. Gromeier M; Nair SK Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. Kazemi Shariat Panahi H; Dehhaghi M; Lam SS; Peng W; Aghbashlo M; Tabatabaei M; Guillemin GJ Semin Cancer Biol; 2022 Nov; 86(Pt 3):1122-1142. PubMed ID: 34004331 [TBL] [Abstract][Full Text] [Related]
8. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas. Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Wollmann G; Ozduman K; van den Pol AN Cancer J; 2012; 18(1):69-81. PubMed ID: 22290260 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate. Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF mBio; 2018 Sep; 9(5):. PubMed ID: 30228241 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses. Sosnovtseva AO; Lipatova AV; Grinenko NF; Baklaushev VP; Chumakov PM; Chekhonin VP Bull Exp Biol Med; 2016 Oct; 161(6):821-825. PubMed ID: 27783287 [TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661 [TBL] [Abstract][Full Text] [Related]
14. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. Walton RW; Brown MC; Sacco MT; Gromeier M J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212 [TBL] [Abstract][Full Text] [Related]
15. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? Chiocca EA; Nassiri F; Wang J; Peruzzi P; Zadeh G Neuro Oncol; 2019 Jan; 21(1):14-25. PubMed ID: 30346600 [TBL] [Abstract][Full Text] [Related]
17. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313 [TBL] [Abstract][Full Text] [Related]